←Back to Expert Scholars
Translational Medicine / 转化医学Emerging Lung Targets
Paul Paik
MD
🏢Memorial Sloan Kettering Cancer Center🌐USA
Clinical Director, Thoracic Oncology
50
h-index
0
Key Papers
0
Key Contributions
👥Biography 个人简介
Paul Paik is a thoracic oncologist who helped define MET exon 14 skipping as a targetable oncogene in NSCLC. He led pivotal studies that paved the way for tepotinib and capmatinib approvals. His research continues to map rare driver mutations and combination therapy strategies.
Share:
🧪Research Fields 研究领域
MET exon 14 skipping
Squamous NSCLC
Targeted therapy
Biomarker development
Precision oncology
🎓Key Contributions 主要贡献
Representative Works 代表性著作
📄Data Sources 数据来源
Last updated: 2026-04-01 | All information from publicly available academic sources
Related Experts 相关专家
Antoni Ribas
UCLA Jonsson Comprehensive Cancer Center
Melanoma ImmunotherapyCheckpoint Inhibitors
Drew M. Pardoll
Johns Hopkins University
Cancer ImmunologyPD-1/PD-L1 Pathway
Padmanee Sharma
MD Anderson Cancer Center
Bladder Cancer ImmunotherapyImmune Profiling
Naiyer A. Rizvi
Columbia University Irving Medical Center
Lung Cancer ImmunotherapyTumor Mutational Burden
关注 Paul Paik 的研究动态
Follow Paul Paik's research updates
留下邮箱，当我们发布与 Paul Paik（Memorial Sloan Kettering Cancer Center）相关的新研究或访谈时，我们会通知你。
Explore More Experts
Discover the researchers shaping the future of cancer treatment